Status:
UNKNOWN
Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Autism Spectrum Disorder
Lead Sponsor:
Guangdong Women and Children Hospital
Conditions:
Safety Issues;Effect of Drugs
Eligibility:
All Genders
2+ years
Phase:
PHASE1
Brief Summary
To study the clinical efficacy and safety of autologous umbilical cord blood transfusion in the treatment of autism spectrum disorder.
Detailed Description
This is a Phase 1 clinical trial that constitutes two time points cohorts with participants who will receive intravenous autologous umbilical cord blood and 0.9% sodium chloride respectively. The timi...
Eligibility Criteria
Inclusion
- • A patient who was diagnosed with ASD.
Exclusion
- • In case a patient underwent a surgical procedure, or was administered autologous cord blood within one year before participating in a clinical trial.
- Accompanied by a serious disease, such as chromosome abnormality, etc.
- In case where a patient's medical condition is judged to be maladapted by a researcher.
- In case a patient or his or her legal representative doesn't agree to participation in a clinical trial.
- A patient having a predisposition to allergies.
- A patient having serious disorders in the liver, kidney, and cardiopulmonary function.
Key Trial Info
Start Date :
July 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04768816
Start Date
July 1 2019
End Date
December 31 2024
Last Update
February 24 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangdong Women and Children's Hospital and Health Institute
Guangzhou, Guangdong, China, 510010